Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001104659-18-042319
Filing Date
2018-06-26
Accepted
2018-06-26 17:00:39
Documents
1
Period of Report
2018-06-22

Document Format Files

Seq Description Document Type Size
1 4 a4.html 4  
1 4 a4.xml 4 3877
  Complete submission text file 0001104659-18-042319.txt   5410
Mailing Address C/O INTERCEPT PHARMACEUTICALS, INC. 18 DESBROSSES STREET NEW YORK NY 10013
Business Address
Duncan Barbara Gayle (Reporting) CIK: 0001353128 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37368 | Film No.: 18919870

Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX 44 1235 430000
Adaptimmune Therapeutics PLC (Issuer) CIK: 0001621227 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)